Non-vitamin K oral anticoagulants (NOACs) are part of a new class of drugs that provide physicians with an alternative to warfarin, a medication with significant bleeding risk. These medications have a therapeutic benefit in patients with non-valvular atrial fibrillation, and include apixaban (Eliquis), dabigatran (Pradaxa), and rivaroxaban (Xarelto). Unlike warfarin, the NOACs do not require […]